TY - JOUR
T1 - A multi-center, real-life experience on liquid biopsy practice for EGFR testing in non-small cell lung cancer (NSCLC) patients
AU - Cortiula, Francesco
AU - Pasello, Giulia
AU - Follador, Alessandro
AU - Nardo, Giorgia
AU - Polo, Valentina
AU - Scquizzato, Elisa
AU - Conte, Alessandro Del
AU - Miorin, Marta
AU - Giovanis, Petros
AU - D’Urso, Alessandra
AU - Girlando, Salvator
AU - Settanni, Giulio
AU - Picece, Vincenzo
AU - Veccia, Antonello
AU - Corvaja, Carla
AU - Indraccolo, Stefano
AU - Maglio, Giovanna De
N1 - Publisher Copyright:
© 2020 by the authors.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/10
Y1 - 2020/10
N2 - Background: circulating tumor DNA (ctDNA) is a source of tumor genetic material for EGFR testing in NSCLC. Real-word data about liquid biopsy (LB) clinical practice are lacking. The aim of the study was to describe the LB practice for EGFR detection in North Eastern Italy. Methods: we conducted a multi-regional survey on ctDNA testing practices in lung cancer patients. Results: Median time from blood collection to plasma separation was 50 min (20–120 min), median time from plasma extraction to ctDNA analysis was 24 h (30 min–5 days) and median turnaround time was 24 h (6 h–5 days). Four hundred and seventy five patients and 654 samples were tested. One hundred and ninety-two patients were tested at diagnosis, with 16% EGFR mutation rate. Among the 283 patients tested at disease progression, 35% were T790M+. Main differences in LB results between 2017 and 2018 were the number of LBs performed for each patient at disease progression (2.88 vs. 1.2, respectively) and the percentage of T790M+ patients (61% vs. 26%).
AB - Background: circulating tumor DNA (ctDNA) is a source of tumor genetic material for EGFR testing in NSCLC. Real-word data about liquid biopsy (LB) clinical practice are lacking. The aim of the study was to describe the LB practice for EGFR detection in North Eastern Italy. Methods: we conducted a multi-regional survey on ctDNA testing practices in lung cancer patients. Results: Median time from blood collection to plasma separation was 50 min (20–120 min), median time from plasma extraction to ctDNA analysis was 24 h (30 min–5 days) and median turnaround time was 24 h (6 h–5 days). Four hundred and seventy five patients and 654 samples were tested. One hundred and ninety-two patients were tested at diagnosis, with 16% EGFR mutation rate. Among the 283 patients tested at disease progression, 35% were T790M+. Main differences in LB results between 2017 and 2018 were the number of LBs performed for each patient at disease progression (2.88 vs. 1.2, respectively) and the percentage of T790M+ patients (61% vs. 26%).
UR - http://www.scopus.com/inward/record.url?scp=85092236157&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092236157&partnerID=8YFLogxK
U2 - 10.3390/diagnostics10100765
DO - 10.3390/diagnostics10100765
M3 - Article
AN - SCOPUS:85092236157
VL - 10
JO - Diagnostics
JF - Diagnostics
SN - 2075-4418
IS - 10
M1 - 765
ER -